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ABSTRACT
Despite the well-recognized role of loss-of-function mutations of the aryl 
hydrocarbon receptor interacting protein gene (AIP) predisposing to pituitary 
adenomas, the pituitary-specific function of this tumor suppressor remains an enigma. 
To determine the repertoire of interacting partners for the AIP protein in somatotroph 
cells, wild-type and variant AIP proteins were used for pull-down/quantitative mass 
spectrometry experiments against lysates of rat somatotropinoma-derived cells; 
relevant findings were validated by co-immunoprecipitation and co-localization. Global 
gene expression was studied in AIP mutation positive and negative pituitary adenomas 
via RNA microarrays. Direct interaction with AIP was confirmed for three known and 
six novel partner proteins. Novel interactions with HSPA5 and HSPA9, together with 
known interactions with HSP90AA1, HSP90AB1 and HSPA8, indicate that the function/
stability of multiple chaperone client proteins could be perturbed by a deficient AIP 
co-chaperone function. Interactions with TUBB, TUBB2A, NME1 and SOD1 were also 
identified. The AIP variants p.R304* and p.R304Q showed impaired interactions 
with HSPA8, HSP90AB1, NME1 and SOD1; p.R304* also displayed reduced binding to 
TUBB and TUBB2A, and AIP-mutated tumors showed reduced TUBB2A expression. 
Our findings suggest that cytoskeletal organization, cell motility/adhesion, as well as 
oxidative stress responses, are functions that are likely to be involved in the tumor 
suppressor activity of AIP.
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INTRODUCTION
The aryl hydrocarbon receptor interacting protein 
(AIP) is a highly conserved co-chaperone with a poorly 
characterized tumor suppressor function [1–3]. Germline 
mutations in the AIP gene (AIPmuts) resulting in a 
truncated and/or unstable AIP protein are the most common 
genetic cause of pituitary adenomas affecting teenagers and 
young adults, presenting either as familial isolated pituitary 
adenoma (FIPA) or as simplex cases of acromegaly or 
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gigantism [4–7]. Despite the ubiquitous expression of the 
AIP protein, no other tumor types have been consistently 
associated with AIPmuts. This apparent tissue selectivity 
could perhaps be explained by a tumor suppressor function 
that is due to pituitary-specific interactions, rather than a 
tissue-specific expression pattern.
The human AIP protein (UniProt O00170) is a 37 
kDa/330 amino acid protein composed of an amino (N)-
terminal peptidyl-prolyl cis-trans isomerase (PPIase)-
like domain, with no enzymatic activity, and a carboxyl 
(C)-terminal tetratricopeptide repeat (TPR) domain 
containing three TPR motifs and a C-terminal alpha 7 
helix [8–12]. The best-known function of AIP is to form 
part, together with the heat-shock protein HSP90 and the 
co-chaperone translationally-controlled tumor protein 
(TCTP), of the multiprotein complex that regulates the 
nuclear translocation of the aryl hydrocarbon receptor 
(AHR) [8, 13–19]. In addition to HSP90, AIP also serves 
as a co-chaperone for other molecular chaperones, such as 
HSPA8 and mitochondrial import receptor subunit TOM20 
homolog (TOMM20) [11, 20–22]. It has been proposed 
that the AIP/HSPA8 complex would bind unfolded 
mitochondrial pre-proteins; AIP should facilitate the 
transfer of such pre-proteins to TOMM20, enabling their 
folding and mitochondrial translocation [20].
Nevertheless, AIP displays a promiscuous repertoire 
of molecular interactions, including at least two viral 
proteins, and a variety of human proteins, (Table 1), but 
none of them has an obvious pituitary-specific function 
(reviewed in [23]) [24–26]). To elucidate the organ-specific 
physiological function of AIP in the pituitary gland, and to 
explore the role of AIP in the pathways that drive pituitary 
tumorigenesis, we aimed to identify the molecular partners 
of AIP in the pituitary gland using a proteomic approach. 
RESULTS
Candidate AIP partners and differential 
interactions among AIP variants
We synthesized N-terminally glutathione-S-
transferase (GST)-tagged AIP proteins, including the 
human wild-type (WT) protein and the variants p.C238Y, 
p.K266A, p.A299V, p.R304* and p.R304Q (Table 2), and 
a GST-only negative control. Using these proteins as baits, 
pull-down experiments were performed in lysates from rat 
somatotropinoma-derived cells (GH3). Tandem mass tags 
were used to label the bound proteins, which were pooled 
together and analyzed by mass spectrometry (MS). Results 
were filtered for significance, normalized against the 
negative control, and compared against the WT experiment. 
Human homologues of these candidate AIP partners were 
identified and grouped in signaling pathways.
The manually validated qualitative MS results 
(Supplementary Table 1) accounted for a total of 514 
different peptides, matching 154 proteins in addition to 
AIP itself. After applying selection filters, 30 proteins were 
identified as candidate partners for WT AIP (Table 3). 
Pathway analysis identified “Remodeling of the epithelial 
adherens junction” as the top canonical pathway (Figure 1A), 
including AIP and 19 of its candidate partners within a 
single network (Figure 1B). As expected from its previously 
reported unstable behavior [7], the synthetic p.C238Y AIP 
protein formed aggregates that precluded its use in our 
experiments. The repertoire of binding peptides varied 
among the pull-down experiments for the rest of the AIP 
variants; quantitative differences in the intensity values of 
the peptides were interpreted as differential binding of the 
corresponding proteins for each bait AIP protein (Figure 1C 
and Supplementary Table 2). Proteins selected for further 
validation experiments (co-immunoprecipitation [co-IP] 
and co-localization) included both novel AIP interacting 
partners and known partners with apparent lost interactions 
in the pull-down experiments for AIP mutants. 
AIP interacts with multiple molecular 
chaperones of the HSP70 and HSP90 families 
Two of the best-known molecular partners of AIP, 
the heat-shock proteins HSP90 and HSPA8 (HSC70), were 
detected in the pull-down experiments. Co-IP experiments 
for AIP and both the inducible (HSPA90AA1 [HSP90-
alpha]) and the constitutive (HSP90AB1 [HSP90-beta]) 
isoforms of HSP90 [27] and with HSPA8 were carried out 
and confirmed (Figure 2A–2C). Loss of HSPA8 binding to 
the AIP mutant p.R304* (Figure 2D) was also confirmed, 
supporting the reliability of our approach with pull-down 
experiments and comparative analysis for assuming 
loss of protein-protein interactions. Novel interactions 
of AIP with two other members of the HSP70 family, 
HSPA5 (also known as 78 kDa glucose-regulated protein 
[GRP-78]) and HSPA9 (mitochondrial HSP70, GRP-75, 
mortalin), were also detected by pull-down and confirmed 
by co-IP (Figure 2E and 2F). Co-localization of AIP and 
HSPA9 in the mitochondrial network was verified by 
immunocytofluorescence (Figure 2G).
The pituitary-specific function of AIP could 
occur via chaperone client proteins
Some pituitary-specific effects of AIP could be 
exerted via indirect interactions with client proteins of 
molecular chaperones. Therefore, a possible indirect 
interaction of AIP with the cyclic adenosine monophosphate 
(cAMP)-dependent protein kinase catalytic subunit alpha 
(PRKACA), an HSP90 client protein with an important 
role in the somatotroph cell function, was explored. AIP and 
PRKACA did not interact directly (Figure 2H), but when a 
triple co-IP experiment with AIP, PRKACA and HSP90AA1 
was performed, the three proteins were successfully co-
immunoprecipitated (Figure 2H–2I), and cytoplasmic co-
localization of AIP and PRKACA was observed (Figure 2J). 
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Table 1: Proven and putative human interacting partners of AIP  (human proteins only)*
UniProt entry Protein name (gene) Experimental method References
P60709 Actin, cytoplasmic 1 (ACTB)¶ AC-MS [64]
Q9UL18 Argonaute RISC catalytic component 1 (AGO1) AC-MS, co-IP [95]
P35869 Aryl hydrocarbon receptor (AHR)
Co-IP [8, 64, 96]
RC [8, 9, 16, 97]
2H [8, 16, 98]
P27540 Aryl hydrocarbon receptor nuclear translocator (ARNT)†
Co-IP [64]
RC [16, 57]
2H [9]
O15392 Baculoviral IAP repeat-containing protein 5 (BIRC5) AC-MS, co-IP [21]
Q9BXL7 Caspase recruitment domain-containing protein 11 (CARD11) 2H, co-IP [99]
Q96HB5 Coiled-coil domain containing protein 120 (CCDC120) AC-MS [100]
Q16543 Hsp90 co-chaperone cell division cycle 37 (CDC37) AC-L, AC-MS [101]
P50750 Cyclin-dependent kinase 9 (CDK9) AC-MS [61, 100]
Q9BXN2 C-type lectin domain family 7, member A (CLEC7A) 2H [102]
P68400 Casein kinase 2, alpha 1 polypeptide (CSNK2A1) BA [103]
Q9NVR5 Protein kintoun (DNAAF2) AC-L, AC-MS [101]
P00533 Epidermal growth factor receptor (EGFR) PCA [104]
P41091 Eukaryotic translation initiation factor 2 subunit 3 (EIF2S3) Co-F [105]
P03372 Oestrogen receptor (ESR1) Co-IP [106]
Q9UK99 F-box only protein 3 (FBXO3) Co-IP, AC-MS [7]
P50395 Rab GDP dissociation inhibitor beta (GDIB) Co-F [107]
Q14344 Guanine nucleotide-binding protein subunit alpha 13 (GNA13) RC, 2H [108]
P50148 Guanine nucleotide-binding protein G(q) subunit alpha (GNAQ) RC [108]
P11142 Heat shock cognate 71 kDa protein (HSPA8) Co-IP [20]
P07900 Heat shock protein 90-alpha (HSP90AA1)
AC-L, AC-MS [101]
RC [52, 57, 97]
P08238 Heat shock protein 90-beta (HSP90AB1)
AC-L, AC-MS [101]
Co-IP [9, 18, 20, 55, 57, 97, 109–111]§
P38646 Stress-70 protein, mitochondrial (HSPA9) Co-F [105]
Q9Y6K9 NF-kappa-B essential modulator (IKBKG) 2H [112]
Q92985 Interferon regulatory factor 7 (IRF7)
AC-MS, RC [113]
Co-IP [114] 
P11279 Lysosome-associated membrane glycoprotein 1 (LAMP1) Co-F [105]
Q9NZR2 Low-density lipoprotein receptor-related protein 1B (LRP1B) 2H, co-IP [115]
Q9NXB0 Meckel syndrome type 1 protein (MKS1) PL-MS [116]
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UniProt entry Protein name (gene) Experimental method References
Q6IA69 Glutamine-dependent NAD(+) synthetase (NADSYN1) AC-L, AC-MS [101]
Q86SG6 Serine/threonine-protein kinase Nek8 (NEK8) PL-MS [116]
Q8WWR8 Sialidase-4 (NEU4) AC-MS [100]
O75161 Nephrocystin-4 (NPHP4) PL-MS [116]
P08235 Mineralocorticoid receptor (NR3C2) Co-IP [111]
O75665 Oral-facial-digital syndrome 1 protein (OFD1) PL-MS [116]
P27815 cAMP-specific 3’,5’-cyclic phosphodiesterase 4A (PDE4A)
2H [30, 90, 117]
Co-IP [117]
O00408 cGMP-dependent 3’,5’-cyclic phosphodiesterase 2A (PDE2A) 2H, co-IP, co-loc [118]
Q15181 Inorganic pyrophosphatase (PPA1) Co-F [119]
Q9H2U2 Inorganic pyrophosphatase 2, mitochondrial (PPA2) Co-F [119]
Q07869 Peroxisome proliferator-activated receptor alpha (PPARA) Co-IP, RC [120]
O75170 Serine/threonine-protein phosphatase 6 regulatory subunit 2 (PPP6R2) PL-MS [121]
O60809 PRAME family member 10 (PRAMEF10) AC-MS [100]
Q5VTA0 PRAME family member 10 (PRAMEF17) AC-MS [100]
P48147 Prolyl endopeptidase (PREP) Co-F [119]
Q15185 Prostaglandin E synthase 3 (PTGES3)
AC-L, AC-MS [101]
Co-IP [111]
P07949 Rearranged during transfection tyrosine-kinase receptor (RET) Co-IP, PCA [122]
P31948 Stress-induced phosphoprotein 1 (STIP1) RC [52]
Q9Y2Z0 Suppressor of G2 allele of SKP1 homolog (SUGT1) AC-L, AC-MS [101]
P13385 Teratocarcinoma-derived growth factor 1 (TDGF1) AC-MS [100]
Q59H18 TNNI3 interacting kinase (TNNI3K) 2H [123]
Q15388 Mitochondrial import receptor subunit TOM20 homolog (TOMM20)
2H, co-IP [20]
RC [11]
P10828 Thyroid hormone receptor beta (THRB) 2H [124]
P0CG48 Polyubiquitin C (UBC) AC-MS [125–129]
Q6PHR2 Serine/threonine-protein kinase ULK3 (ULK3) AC-MS [100]
O94966 Ubiquitin specific peptidase 19 (USP19) AC-L, AC-MS [101]
P07947 Tyrosine-protein kinase Yes (YES1) AC-MS [100]
2H: two-hybrid assay, AC-L: Affinity capture-luminescence, AC-MS: affinity capture (pull-down)-mass spectrometry, 
BA: biochemical activity (an interaction is inferred from the biochemical effect of one protein upon another), co-F: 
co-fractionation, co-IP: co-immunoprecipitation (affinity capture-Western blot), co-loc: co-localization, PCA: protein-
fragment complementation assay, PL-MS: proximity label-mass spectrometry, RC: reconstituted complex (an interaction 
is detected between two proteins in vitro). Detailed explanation of all the experimental methods: http://wiki.thebiogrid.org/
doku.php/experimental_systems. 
*Includes proteins detected either by direct protein-protein interaction experiments or as part of datasets from high-throughput 
proteomic studies reported in the literature and/or in the Biological General Repository for Interaction Datasets [26].
¶Contradictive results, a direct interaction between AIP and ACTB was disproven by a different study [65]. 
†Contradictive results, a direct interaction between AIP and ARNT was disproven by different studies [8, 16, 109].
§These studies did not specify the isoform of HSP90 analyzed or used a peptide that is common to HSP90AA1 and 
HSP90AB1. 
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Table 2: AIP variants selected for the study
Variant*
Minor allele 
frequency 
(ExAc)*
Location in 
protein Clinical data Experimental data Classification
c.713G>A, p.C238Y
(chr11:67257854G>A) 0.000008 TPR2 domain
Detected in one FIPA 
family with three cases of 
acromegaly (1.4% of the 
AIPmut positive cases in 
our cohort) [6, 90, 130, 
131].
Results in an unstable protein, probably 
due to abnormal packaging of the alpha 
and beta-helices in the second TPR 
motif [7, 11], with reduced ability for 
blocking cell proliferation [90], as well 
as complete disruption the AIP-PDE4A5 
interaction [30, 131]. This variant is 
unable to rescue the lethality caused by 
CG1847 knockout in a fruit fly model 
[132].
Pathogenic
c.796_797delinsGC, 
p.K266A
(chr11:67258267_67258
268delinsGC) 
NA TPR3 domain Not detected in patients.
Disrupts the interaction of AIP with 
HSP90. Loss of HSP90 binding 
significantly reduces the ability of AIP 
to interact with AHR, but it is unknown 
if this affects other signaling pathways 
[55].
Experimental
c.896C>T, p.A299V
(chr11:67258367C>T) 0.000428 TPR3 domain
Clinical evaluation of 
multiple carriers does not 
support a pathogenic role 
for this rare SNP [131]. It 
was found in trans with a 
truncating AIP mutation 
in two subjects without 
pituitary adenomas. 
Detected in 0.8% of the 
individuals in our cohort 
(one patient and four 
unaffected members of a 
single FIPA family) [6]. 
Although in silico analysis predicted a 
possible disruption of protein folding, 
this variant results in a stable protein, 
displaying only slight reduction in 
PDE4A5 binding [7, 30, 131]. Acting 
similarly to the wild-type protein, this 
variant is able to rescue the lethality in a 
CG1847 knockout fruit fly model [132].
Non-pathogenic
 c.910C>T, p.R304* 
(chr11:67258381C>T) 0.000017 TPR3 domain
Most common AIP 
mutation associated with 
familial and sporadic 
pituitary adenomas 
(35.9% of all the AIPmut 
positive cases in our 
cohort) [6]. Founder 
effect in the Northern 
Irish [133, 134] and 
Northern Italian [135] 
populations.
This nonsense mutation is translated into 
a truncated, unstable protein, resulting 
in half the normal total AIP content in 
cells from heterozygous carriers [7, 
136]. Causes complete disruption of 
the PDE4A5 binding and loss of the 
ability of the mutant AIP to block cell 
proliferation [30, 90], and impaired 
ability to suppress cAMP signaling in 
response to forskolin [2]. 
Pathogenic
c.911G>A, p.R304Q
(chr11:67258382G>A) 0.001458** TPR3 domain
Found for the first time 
in an apparently sporadic 
case of Cushing’s disease 
[137], and subsequently 
in several young-onset 
and familial cases, this 
variant is not rare among 
AIP pituitary adenoma 
patients (second most 
common in our cohort, 
found in 7.9% of the 
AIPmut cases) [6]. 
Two subjects in ExAc 
carry this variant in 
homozygosis.
Relatively conservative, changing a 
longer side chain, positively charged 
amino acid, to a slightly shorter, 
uncharged, hydrophilic one at the 
C-terminal alpha-7 helix [11]. The 
protein displays normal half-life [7]. 
Partially disrupts PDE4A5 binding [30]. 
Retains the ability to rescue the lethality 
caused by CG1847 knockout in the fruit 
fly [132].
Variant of 
unknown 
significance
NA, not available.
*All the variants are annotated in the GRCh37/hg19 human genome assembly using the reference transcript NM_003977.3.
**Includes two homozygous individuals.
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Table 3: Candidate AIP partners and peptides identified by quantitative MS and their human homologues
# R. norvegicus proteins Human homologues
UniProt 
entry
Protein description 
(gene name) Mass (kDa) Peptides identified
% of 
identity
UniProt 
entry
Protein description 
(gene name)
Mass 
(kDa)
1 P60711 ACTB_RAT Actin, cytoplasmic 1(Actb) 41.7
VAPEEHPVLLTEAPLNPKANR
100 P60709
ACTB_HUMAN 
Actin, cytoplasmic 1 
(ACTB)
41.7
KDLYANTVLSGGTTMYPGIADR
2 P29419
ATP5I_RAT ATP 
synthase subunit e, 
mitochondrial (Atp5i)
8.3 ELAEAEDVSIFK 83 P56385
ATP5I_HUMAN ATP 
synthase subunit e, 
mitochondrial (ATP5I)
7.9
3 P15999
ATPA_RAT ATP 
synthase subunit 
alpha, mitochondrial 
(Atp5a1)
59.8 VGLKAPGIIPR 97 P25705
ATPA_HUMAN 
ATP synthase subunit 
alpha, mitochondrial 
(ATP5A1)
59.8
4 P35434
ATPD_RAT ATP 
synthase subunit delta, 
mitochondrial (Atp5d)
17.6 ANLEKAQSELSGAADEAAR 87 P30049
ATPD_HUMAN 
ATP synthase subunit 
delta, mitochondrial 
(ATP5D)
17.5
5 P47727
CBR1_RAT Carbonyl 
reductase [NADPH] 
1 (Cbr1)
30.6
EDKILLNACCPGWVR
86 P16152 
CBR1_HUMAN 
Carbonyl reductase 
[NADPH] 1 (CBR1)
30.4
ELLPIIKPQGR
GHEAVKQLQTEGLSPR
GVHAKEGWPNSAYGVTKIGVTVLSR
KFLGDVVLTAR
REDKILLNACCPGWVR
SCSPELQQKFR
6 P08649 CO4_RAT Complement C4 (C4) 192 ADLEKLTSLSDR 80 P0C0L4 
CO4A_HUMAN 
Complement C4-A 
(C4A)
193
7 Q497C3
CP013_RAT UPF0585 
protein C16orf13 
homolog
22.6
MVDMPANNKCLIFR
90 Q96S19 
CP013_HUMAN 
UPF0585 protein 
C16orf13 (C16orf13)
22.6
NKEPILCVLR
8 P63255
CRIP1_RAT 
Cysteine-rich protein 
1 (Crip1)
8.6 GGAESHTFK 97 P50238 
CRIP1_HUMAN 
Cysteine-rich protein 
1 (CRIP1)
8.5
9 Q68FR6
EF1G_RAT 
Elongation factor 
1-gamma (Eef1g)
50.1
KLDPGSEETQTLVR
98 P26641
EF1G_HUMAN 
Elongation factor 
1-gamma (EEF1G)
50.1
AFKALIAAQYSGAQIR
ILGLLDTHLKTR
KFPAGKVPAFEGDDGFCVFESNAIAY
YVSNEELR
10 D4ABP9 FBX3_RAT F-box only protein 3 (Fbxo3) 55.4
EEDLDAVEAQIGCKLPDDYR
91 Q9UK99
FBX3_HUMAN 
F-box only protein 3 
(FBXO3)
54.6
ITNAKGDVEEVQGPGVVGEFPIISPGR
11 Q99PF5
FUBP2_RAT Far 
upstream element-
binding protein 2 
(Khsrp)
74.2 KDAFADAVQR 98 Q92945
FUBP2_HUMAN Far 
upstream element-
binding protein 2 
(KHSRP)
73.1
12 P48721
GRP75_RAT 
Stress-70 protein, 
mitochondrial (Hspa9)
73.9
EMAGDNKLLGQFTLIGIPPAPR
98 P38646
GRP75_HUMAN 
Stress-70 protein, 
mitochondrial 
(HSPA9)
73.7
QATKDAGQISGLNVLR
MPKVQQTVQDLFGR
KDSETGENIR
QAVTNPNNTFYATKR
13 P06761
GRP78_RAT 78 kDa 
glucose-regulated 
protein (Hspa5)
72.3
KSDIDEIVLVGGSTR
98 P11021
 GRP78_HUMAN 78 
kDa glucose-regulated 
protein (HSPA5)
72.3
IINEPTAAAIAYGLDKR
NQLTSNPENTVFDAKR
AKFEELNMDLFR
14 P34058
HS90B_RAT Heat 
shock protein HSP 90-
beta (Hsp90ab1)
83.3 ELISNASDALDKIR 99 P08238
HS90B_HUMAN 
Heat shock protein 
HSP 90-beta 
(HSP90AB1)
83.3
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AIP is involved in cytoskeletal organization 
Multiple cytoskeletal proteins were identified in 
the pull-down experiments. Although these proteins are 
abundantly expressed in every cell type and could therefore 
represent experimental artifacts, some of them displayed 
differential binding between WT and mutant AIP proteins, 
suggesting the relevance of these potential interactions. 
# R. norvegicus proteins Human homologues
UniProt 
entry
Protein description 
(gene name) Mass (kDa) Peptides identified
% of 
identity
UniProt 
entry
Protein description 
(gene name)
Mass 
(kDa)
15 P63018
HSP7C_RAT Heat 
shock cognate 71 kDa 
protein (Hspa8)
70.9
MVNHFIAEFKR
99 P11142
HSP7C_HUMAN 
Heat shock cognate 71 
kDa protein (HSPA8)
70.9
QATKDAGTIAGLNVLR
NQVAMNPTNTVFDAKR
GTLDPVEKALR
LIGDAAKNQVAMNPTNTVFDAKR
16 Q5FVL7 KTU_RAT Protein kintoun (Dnaaf2) 89.3 EWYWGLNKDSLEER 65 Q9NVR5
KTU_HUMAN 
Protein kintoun 
(DNAAF2)
91.1
17 Q9QX69 LANC1_RAT LanC-like protein 1 (Lancl1) 45.2 AFPNPYADYNKSLAENYFDSTGR 91 O43813
LANC1_HUMAN 
LanC-like protein 1 
(LANCL1)
45.3
18 Q05982
NDKA_RAT 
Nucleoside 
diphosphate kinase A 
(Nme1)
17.2 TFIAIKPDGVQR 95 P15531
NDKA_HUMAN 
Nucleoside 
diphosphate kinase A 
(NME1)
17.1
19 P19527
NFL_RAT 
Neurofilament light 
polypeptide (Nefl)
61.3
KGADEAALAR
97 P07196
NFL_HUMAN 
Neurofilament light 
polypeptide (NEFL)
61.5
LAAEDATNEKQALQGER
FTVLTESAAKNTDAVR
AAKDEVSESR
QKHSEPSR
20 P63324
RS12_RAT 40S 
ribosomal protein S12 
(Rps12)
14.5 LGEWVGLCKIDR 99 P25398
RS12_HUMAN 40S 
ribosomal protein S12 
(RPS12)
14.5
21 P13471
RS14_RAT 40S 
ribosomal protein S14 
(Rps14)
16.3 TKTPGPGAQSALR 99 P62263
RS14_HUMAN 40S 
ribosomal protein S14 
(RPS14)
16.3
22 P60868
RS20_RAT 40S 
ribosomal protein S20 
(Rps20)
13.4 SLEKVCADLIR 100 P60866
RS20_HUMAN 40S 
ribosomal protein S20 
(RPS20)
13.4
23 P05765
RS21_RAT 40S 
ribosomal protein S21 
(Rps21)
9.1 LAKADGIVSKNF 95 P63220
RS21_HUMAN 40S 
ribosomal protein S21 
(RPS21)
9.1
24 P62859
RS28_RAT 40S 
ribosomal protein S28 
(Rps28)
7.8 NVKGPVREGDVLTLLESER 100 P62857
RS28_HUMAN 40S 
ribosomal protein S28 
(RPS28)
7.8
25 Q6PEC4
SKP1_RAT S-phase 
kinase-associated 
protein 1 (Skp1)
18.7 KTFNIKNDFTEEEEAQVR 99 P63208
SKP1_HUMAN 
S-phase kinase-
associated protein 1 
(SKP1)
18.7
26 P07632
SODC_RAT 
Superoxide dismutase 
[Cu-Zn] (Sod1)
15.9 GGNEESTKTGNAGSR 83 P00441
SODC_HUMAN 
Superoxide dismutase 
[Cu-Zn] (SOD1)
15.9
27 P85108
TBB2A_RAT Tubulin 
beta-2A chain 
(Tubb2a)
49.9 INVYYNEAAGNKYVPR 100 Q13885
TBB2A_HUMAN 
Tubulin beta-2A chain 
(TUBB2A)
49.9
28 Q6P9T8
TBB4B_RAT Tubulin 
beta-4B chain 
(Tubb4b) 
49.8 INVYYNEATGGKYVPR 99 P68371
TBB4B_HUMAN 
Tubulin beta-4B chain 
(TUBB4B)
49.8
29 P69897 TBB5_RAT Tubulin beta-5 chain (Tubb5) 49.7 ISVYYNEATGGKYVPR 100 P07437
TBB5_HUMAN 
Tubulin beta chain 
(TUBB)
49.7
30 Q9Z270
VAPA_RAT Vesicle-
associated membrane 
protein-associated 
protein A (Vapa) 
27.8
FKGPFTDVVTTNLKLQNPSDR
97 Q9P0L0
VAPA_HUMAN 
Vesicle-associated 
membrane protein-
associated protein A 
(VAPA)
27.9
QDGPLPKPHSVSLNDTETR
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Beta-actin (ACTB) was underrepresented in the pull-down 
experiments for the AIP variants p.R304Q and p.R304* 
(normalized intensity values of 0.3 and 0.6, compared with 
the WT protein). Validation of this interaction was attempted 
but, although the co-IP reactions were positive in both 
directions, bands for the co-immunoprecipitated proteins were 
also observed in the mouse IgG negative control, indicating 
a non-specific binding of ACTB to this immunoglobulin 
(Figure 3A). The co-IP experiment between cytoskeletal 
protein neurofilament light polypeptide (NEFL) and AIP 
failed to prove the interaction (Figure 3B). In the HEK293 
cells, ACTB and AIP displayed different distribution patterns, 
although some small areas of perinuclear co-localization 
were observed (Figure 3C), while areas of co-localization for 
AIP and NEFL were observed in only a few cells (Figure 
3D). Interactions of AIP with ACTB and NEFL cannot be 
discarded, but the experimental artifacts and/or the lack of 
consistency between co-IP and co-localization complicate 
data interpretation. 
Two isotypes of beta tubulins were under-represented 
in the pull-down experiment for the mutant p.R304*, 
compared with WT AIP: tubulin beta chain (TUBB) and 
tubulin beta-2A chain (TUBB2A, normalized intensity values 
of 0.2 and 0.3, respectively). Positive co-IP experiments 
were obtained for TUBB and TUBB2A proteins with AIP, 
although the band corresponding to TUBB in the anti-
Figure 1: AIP candidate interacting partners: signaling pathways and differential peptide repertoires in pull-down 
experiments. (A) The top signaling pathway reported by Ingenuity Pathway Analysis when analyzing the 30 candidate interacting 
partners identified for WT AIP (as listed in Table 3) was “Remodeling of the epithelial adherens junction” (P < 0.0001). This pathway 
included five candidate partners (ACTB, NME1, TUBB, TUBB2A, and tubulin beta-4B chain [TUBB4B]) out of the total of 68 proteins 
reported for such pathway by the platform used (overlap: 7.4%). Proteins in this pathway represent multiprotein complexes, with cadherins 
as central components, mediating cell-cell adhesion and intercellular communication, and regulating cell shape and polarity. Other top 
canonical pathways reported by this analysis were “Regulation of eIF4 and p70S6K signaling” (5/157 proteins [3.2%], P < 0.0001), 
“EIF2 signaling” (5/194 [2.6%], P < 0.0001), “mTOR signaling” (5/199 [2.5%], P < 0.0001) and “Protein ubiquitination pathway” (5/255 
[2.5%], P < 0.0001). Proteins marked in pink are among the AIP candidate interacting partners identified by our pull-down experiments. 
F-actin refers to “filamentous actin” (i.e. a polymer of actin molecules, including ACTB among other isoforms) which forms part of 
the cytoskeleton. (B) Nineteen of the AIP WT candidate partners were grouped together in a single network, either due to functional 
relationships or direct binding. (C) Schematic representation of the pull-down data presented in Supplementary Table 2 (in a logarithmic 
scale for easy overview) including only proteins present in the AIP WT experiment. Proteins whose peptides were underrepresented in the 
AIP variant protein pull-down experiments were interpreted as impaired or lost interactions. 
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Myc immunoprecipitation was weak (Figure 3E–3F). In 
the confocal immunocytofluorescence images, TUBB2A 
appeared distributed in cytoplasmic filaments, while AIP 
had predominantly cytoplasmic diffuse distribution, with 
clear overlap of both proteins in the cytoplasmic microtubule 
network (Figure 3G). In addition, a novel interaction between 
AIP and the cytoskeletal organizer/tumor suppressor NME/
NM23 nucleoside diphosphate kinase 1 (NME1) was identified 
by the pull-down experiment, and binding was reduced for 
AIP p.A299V (normalized intensity value: 0.2) and lost for the 
variants p.R304* and p.R304Q. This interaction was validated 
by co-IP, although only when the anti-Myc antibody was used 
for protein detection (Figure 3H). 
Interaction of AIP with SOD1 
A novel interaction between AIP and the 
mitochondrial protein superoxide dismutase [Cu-Zn] 
Figure 2: AIP interacts with multiple proteins from the HSP90 and HSP70 families of molecular chaperones. WT AIP 
interactions with HSP90AA1 (A) and HSP90AB1 (B) were confirmed by co-IP, validating the experimental procedures. Also by co-IP, 
HSPA8 interacted with WT AIP (C), but not with the p.R304* mutant (D), as predicted by the pull-down experiment results. Interactions 
with two novel molecular chaperones were validated by co-IP: HSPA5 (E) and HSPA9 (F). Co-localization of AIP and HSPA9 (G) was 
confirmed in the mitochondrial network, with a Pearson’s R-value of 0.72. (H) AIP does not co-immunoprecipitate with PRKACA, ruling 
out direct interaction of these two proteins. (I) However, in the presence of HSP90AB1, the three proteins co-immunoprecipitate with the 
anti-Myc, anti-HA and anti-Flag antibodies. (J) Areas of co-localization for AIP and PRKACA were detected in the cytoplasm, although 
with a weaker correlation compared with HSPA9, for a Pearson’s R-value of 0.39. For the co-IP experiments a-f and h, the left panels 
represent anti-Myc western blot (WB) membranes and the right panels, anti-HA WB membranes. For the co-IP experiment presented in i the 
additional panel at the extreme right presents an anti-Flag WB membrane. The blue arrows in all the panels represent the protein of interest 
in each WB membrane (Myc-AIP on the left panels, and HA-tagged proteins on the right panels, plus Flag-PRKACA in experiment i). 
The arrowheads in all the panels point out the heavy (top) and light (bottom) chains of mouse immunoglobulins. IP: immunoprecipitation, 
MWM: molecular weight marker. The immunocytofluorescence images (G and J) are reconstructions of representative images of the 
z-stacks obtained, at a 63× magnification. Top left: nuclei (DAPI), top right: HSPA9 (G) or PRKACA (J), bottom left: AIP and bottom right: 
merged image. Inserts in the merged images present 2-D intensity histograms corresponding to the co-localization calculations. 
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(SOD1), absent for the variants p.R304* and p.R340Q, 
was confirmed by co-IP, although a band for SOD1 was 
not observed in the anti-Myc IP when attempting detection 
with an anti-HA antibody (Figure 3H), suggesting a weak 
interaction. 
Negative validation experiments
Negative co-IP experiments were obtained for the 
candidate AIP partners vesicle-associated membrane 
protein-associated protein A (VAPA) and carbonyl 
reductase [NADPH] 1 (CBR1), while inconclusive results 
(due to immunoprecipitation of the protein of interest with 
the negative control IgG) were observed for elongation 
factor 1-gamma (EEF1G). CBR1 binds glutathione and 
EEF1G contains a GST domain [28]. Therefore, it is likely 
that these two proteins were pulled down due to the use 
of a GST/glutathione method and not due to specific AIP 
binding.
Differential expression of AIP interacting 
partners in AIPmut positive somatotropinomas
We performed microarray gene expression analysis 
on samples from AIPmut positive and negative human 
pituitary adenomas and normal pituitaries. We aimed to 
determine whether the identified AIP interacting partners 
played a role in pituitary tumorigenesis, independently 
of AIPmuts, as well as to determine how the expression 
profile could be affected by AIP deficiency. Comparison of 
the gene expression profiles of the AIP candidate partners 
identified in the pull-down experiments revealed that 
members of the beta tubulin family were differentially 
expressed. In particular, TUBB2B was found significantly 
downregulated in AIPmut positive (-8.3-fold change, 
P = 0.0043) and AIPmut negative (-5.2-fold change, 
P = 0.0464) somatotropinomas, compared with the normal 
pituitaries. Likewise, TUBB6B (tubulin beta 6 class V) 
was significantly downregulated in AIPmut negative 
non-functioning pituitary adenomas (NFPAs, -8.4-fold 
change, P = 0.0057 vs. normal pituitary). By contrast, 
TUBB1 (tubulin beta 1 class VI) was upregulated in 
AIPmut positive somatotropinomas (5.16-fold change, P 
= 0.0078 vs. normal pituitary). In addition, upregulation 
of NME1 (2.16-fold change, P = 0.03) and HSPA9 (2.37-
fold change, P = 0.05) was observed in AIPmut positive 
somatotropinomas, compared with normal pituitary. 
There were no significant differences in these results in 
AIPmut positive compared with AIPmut negative pituitary 
adenomas. Expression of the rest of the AIP partners 
identified by pull-down was not statistically significantly 
differentially expressed in AIPmut positive, AIPmut 
negative or sporadic somatotropinomas compared with 
the normal pituitaries. Our full microarray datasets have 
been deposited at the National Center for Biotechnology 
Information’s Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo, accession number GSE63357).
AIP overexpression does not affect AIP 
interacting partners at the transcriptional level 
In contrast to the findings of the microarray analysis, 
overexpression of WT AIP in HEK293 and GH3 cells 
(Supplementary Figure 1A and 1B, respectively) displayed 
no effect on the expression of the interacting partners 
HSPA5, HSPA8, HSPA9, HSP90AA1, HSPA90AB1, 
NME1, SOD1, TUBB and TUBB2A at the RNA level at 
24 hours post-transfection. 
Overexpressed AIP interacting partners have no 
effect on GH3 cell proliferation
Individual overexpression of the AIP interacting 
partners HSPA5, HSPA8, HSPA9, HSP90AA1, 
HSPA90AB1, NME1, SOD1, TUBB and TUBB2A had 
no effect on the proliferation of GH3 cells at 24 and 48 h 
compared with the empty vector control (Supplementary 
Figure 1C). We also compared the results at the two time 
points within each experimental condition, finding that 
overexpression of TUBB2A resulted in reduced cell count 
at 48 h; this effect was not observed for the rest of the genes 
studied.  
DISCUSSION 
We have explored the interactions of AIP with 
other proteins in pituitary cells, and identified six novel 
molecular partners for this co-chaperone: HSPA5, HSPA9, 
TUBB, TUBB2A, NME1 and SOD1. Thus, our results 
expand the list of possible signaling pathways implicated 
in the pituitary-specific tumor suppressior function of AIP. 
Deregulation of the cyclic 3′-5′-adenosine monophosphate/
protein kinase A pathway (cAMP pathway) is a well-
known initiator of somatotroph cell tumorigenesis [29]. 
It has recently been suggested that the anti-tumorigenic 
function of AIP occurs through a regulatory effect on such 
pathway, mediated by G-inhibitory proteins (Giα2/Giα3), 
very likely coupled to somatostatin receptors (SSTRs) 
[2, 3], and probably also via phosphodiesterase function 
regulation [30]. However, while pituitary adenomas/
hyperplasia caused by genetic alterations in components 
of the cAMP pathway (such as GNAS in the McCune-
Albright syndrome and PRKAR1A in Carney complex) 
share similar molecular, histopathological and clinical 
characteristics, AIPmut-related pituitary adenomas 
display distinctive features that point to the involvement 
of additional independent signaling pathways [1, 6, 31]. 
We have demonstrated interactions between AIP 
and four different heat shock proteins: two previously 
known, HSP90 and HSPA8, and two novel molecular 
partners, HSPA5 and HSPA9. The latter ones have 
specific subcellular distributions, in sharp contrast with 
the wide cytoplasmic and nuclear distribution of HSPA8 
and HSP90. HSPA5 is a molecular chaperone resident 
in the endoplasmic reticulum involved in protein quality 
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control and in the unfolded protein response [32]. This 
cellular response triggers the degradation of unfolded 
proteins and eliminates cells subjected to prolonged stress 
but, if sustained, it may elicit the selective proliferation 
of transformed cells with anti-apoptotic and angiogenic 
abilities [32–36]. HSPA5 overexpression in cancer is 
associated with poor prognosis and drug resistance, and 
represents a novel therapeutic target [37–39]. No previous 
data exist on the role of HSPA5 on pituitary function, but 
in a rat gliosarcoma cell line HSPA5 expression is induced 
by cAMP-responsive protein kinases [40]. If such kinases 
stimulate HSPA5 expression also in the pituitary gland, 
this chaperone could amplify the pro-tumorigenic effect 
of the pathway and the interaction with AIP could regulate 
its subcellular localization.
Originally identified as a mitochondrial chaperone, 
HSPA9 is also present in other subcellular localizations, 
particularly in neoplastic tissues [41–43]. This heat-shock 
Figure 3: Interactions of AIP with cytoskeletal proteins, the cytoskeletal organizer and tumor suppressor NME1, and 
the enzyme SOD1. (A) A co-IP experiment for AIP and ACTB showed inconclusive results, as the protein was precipitated by the IgG 
negative control. (B) Co-IP for AIP and NEFL rendered negative results. (C) ACTB and AIP displayed different distribution patterns in 
the cell and co-localized only in small perinuclear areas, for a Pearson’s R-value of 0.17. (D) Likewise, only small areas of co-localization 
in a few cells were identified for AIP and NEFL, for a Pearson’s R-value of 0.38. Positive co-IP experiments were obtained for TUBB (E) 
and TUBB2A (F), although the band representing HA-TUBB when immunoprecipitating with an anti-Myc antibody was weak. (G) AIP 
and TUBB2A clearly co-localize in the cytoplasm, particularly in the perinuclear area (Pearson’s R-value of 0.54). (H) Positive co-IP of 
AIP and NME1 was observed, although only when the proteins were detected using the anti-Myc antibody. (I) Likewise, co-IP of AIP and 
SOD1 was observed only when detection was performed using the anti-Myc antibody, but not when using the anti-HA antibody. For the 
co-IP experiments a, b, e, f and h, the left panels represent anti-Myc WB membranes and the right panels, anti-HA WB membranes. The 
blue arrows in all the panels represent the protein of interest in each WB membrane (Myc-AIP on the left panels, and HA-tagged proteins 
on the right panels). The arrowheads in all the panels point out the heavy (top) and light (bottom) chains of mouse immunoglobulins. 
IP: immunoprecipitation, MWM: molecular weight marker. The immunocytofluorescence images (c, d and g) are reconstructions of 
representative images of the z-stacks obtained, at a 63× magnification. Top left: nuclei (DAPI), top right: ACTB (c), NEFL (d), or TUBB2A 
(g); bottom left: AIP and bottom right: merged image. Inserts in the merged images present 2-D intensity histograms corresponding to the 
co-localization calculations. 
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protein is involved in the translocation of proteins from the 
cytosol into the mitochondrial matrix, in the folding of such 
imported proteins and in the response to oxidative stress 
[44, 45]. Deletion of the HSPA9 locus (5q31.1) is a frequent 
finding in myeloid malignancies [46]. In other settings, 
HSPA9 exhibits oncogenic properties, making it a potential 
therapeutic target for cancer. For instance, overexpressed 
HSPA9 can sequester TP53 in the cytoplasm [43, 47], 
inhibit CDKN1A [48, 49], and activate hTERT [50]. Besides 
the multiple studies addressing the HSPA9 functions in 
normal and neoplastic cells, little is known about the co-
chaperones that regulate its subcellular localization and 
function, and its expression pattern in the pituitary gland 
has not been assessed. AIP is a direct partner for TOMM20, 
located on the mitochondrial surface, and thus the novel 
interaction with HSPA9 expands the regulatory role of AIP 
in two different steps of the mitochondrial protein-import 
machinery [51]. 
The highly conserved and abundant chaperone 
HSP90 regulates a wide variety of cellular pathways via 
interactions with multiple client proteins [52, 53]. When 
overexpressed in ACTH-secreting pituitary adenomas, 
HSP90 impairs the sensitivity of the glucocorticoid 
receptor and therefore adrenal-pituitary negative feedback 
[54]. However, the role of HSP90 in AIPmut-associated 
pituitary adenomas has not been explored. It has previously 
been shown that the highly conserved AIP residues G272 
and K266 are required for the two proteins to interact [55, 
56], but under our experimental conditions, AIP p.K266A 
did not impair the binding, while mutations affecting 
the C-terminal alpha-helix of the protein (p.R304* and 
p.R304Q) did so. Although these variants do not affect 
the HSP90 binding site directly, an abnormal C-terminal 
alpha-helix could possibly alter the folding of the third 
TPR motif, affecting the three-dimensional structure of 
the TPR-binding site and thus the interaction with HSP90. 
Previously reported co-IP experiments [57], and now our 
data, indicate that, despite the fact that the PPIase domain 
of AIP can also bind HSP90 [58], the integrity of not only 
the TPR motifs but also of the C-terminal alpha-helix is 
crucial for this interaction to occur. 
Via interactions with multiple co-chaperones, 
HSPA8 coordinates the dynamics of clathrin-coated 
vesicles, influences the cell cycle through cyclin D1 and is 
implicated in protein translocation and quality control [59, 
60]. In the absence of the aryl hydrocarbon receptor (AHR), 
AIP preferentially binds HSPA8 instead of HSP90 and 
contributes to the prevention of the aggregation of cytosolic 
proteins, such as mitochondrial pre-proteins synthesized 
in the cytoplasm, which are then transferred to TOMM20, 
enabling their folding and mitochondrial translocation 
[20–22]. HSPA8 was the most consistently represented AIP 
partner among pull-down experiments, and it was strikingly 
affected by AIP p.R304*. The physiological importance 
of this direct interaction between HSPA8 and AIP in the 
pituitary gland remains undetermined.
The TPR domain of AIP displays binding sites 
for the MEEVD conserved sequence of HSP90, for the 
C-terminal motif IEEVD of HSPA8, and EDDVE of 
TOMM20 [11]. Interestingly, neither HSPA5, nor HSPA9 
contain such conserved motifs, and none of the AIP variants 
studied disturbed these interactions. Given the prominent 
role of these chaperones in protein folding, a role for AIP 
as a mediator of the protein quality control system in 
the pituitary gland could be expected. Both HSP90 and 
HSPA8 are ubiquitously expressed, but their interacting 
partners include proteins with tissue-specific functions 
and/or expression patterns. The interaction between 
HSP90 and PRKACA was reported previously as part of 
a high throughput proteomic study, but it was not further 
functionally or structurally characterized [61]. Our data here 
support this interaction. The HSP90/AIP complex could 
feasibly regulate PKA localization, and it could possibly 
also interact with the regulatory subunits of PKA, as it has 
recently been proposed [62]. 
The second group of AIP partners identified is 
composed of cytoskeletal proteins. While very weak 
or negative binding of the PPIase-like domain of AIP 
to dynein was found previously [63], a different study 
demonstrated that the AIP-mediated cytoplasmic 
localization of the AHR requires the anchoring of the 
complex to actin filaments [64]. The latter study showed 
direct binding of AIP to ACTB when AHR is inactive, but 
a different group reported conflicting results regarding 
such an interaction [65]. Unfortunately, we cannot shed 
light on this issue, due to non-specific binding of ACTB 
to IgG, although perinuclear co-localization was seen on 
immunostaining. Likewise, the interaction of AIP with 
NEFL could not be clearly validated or ruled out (negative 
co-IP, despite positive co-localization in some cells). 
Composed of heterodimers of various alpha and 
beta-tubulins, microtubules are structures involved in 
cell movement, intracellular transport (including vesicle 
trafficking) and cell division and are targets of anti-mitotic 
drugs [66–69]. In the pituitary gland, the cytoskeletal 
network plays a crucial role in regulating the function of 
signal transduction. It has been suggested that low levels 
of filamin A, a cytoskeletal-associated protein, could 
represent a post-receptor mechanism of pharmacological 
resistance in pituitary adenomas, as this scaffolding 
protein stabilizes the SSTR2 and dopamine 2 receptor, 
linking them to their intracellular effectors [69, 70]. We 
validated direct interactions of AIP with two isotypes of 
tubulins: TUBB, widely expressed, and TUBB2A, the 
major isotype in neural tissue [67]. Interestingly, two 
isotypes of beta tubulin were also deregulated (TUBB1 
with five-fold upregulation and TUBB2B with eight-fold 
downregulation) in AIP-mutated somatotroph tumors, 
compared with normal pituitaries. These results point 
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towards a role for AIP as a regulator of the microtubule 
network, with possible implications for post-receptor 
signal transduction and hormone secretion. 
NME1 (granzyme A-activated DNase, metastasis 
inhibition factor nm23), the first metastasis suppressor gene 
identified [71–73], is a tumor suppressor that negatively 
regulates cell migration/motility and inhibits the cell cycle 
through downregulation of cyclin B, an effect inhibited by 
cAMP [74]. This protein phosphorylates kinase suppressor 
of Ras 1 (KSR1), thereby inactivating the RAS/RAF/MEK/
ERK signaling pathway [75]. NME1 mRNA levels are high 
in cell lines with low metastatic potential [71], while LOH 
involving the NME1 locus (17q21.3) has the opposite effect 
[76]. Low NME1 expression correlates with metastasis and 
poor clinical prognosis in different human epithelial cancer 
types [77]. Moreover, NME1 knockdown in various human 
cancer cell lines disrupts E-cadherin-mediated cell adhesion, 
leading to nuclear translocation of beta-catenin [78], while 
its overexpression inhibits the metastatic potential of TP53-
deficient cells [73]. NME1 co-localizes with E-cadherin in 
epithelial cancer cell lines, suggesting a possible role on 
the stabilization of the adherens junctions [78]. In pituitary 
adenomas, NME1 expression inversely correlates with 
tumor extension into the cavernous sinus [79], but there 
are no data available on its expression pattern in different 
pituitary adenoma subtypes. Since AIPmut positive pituitary 
adenomas are frequently invasive, the interaction with AIP 
should have a regulatory effect on this kinase [80]. 
Interestingly, “Remodeling of the epithelial adherens 
junction” was identified as the top molecular pathway 
encompassing our candidate AIP interacting partners. Loss 
of the integrity of epithelial adherens junctions results in 
epithelial-mesenchymal transition (EMT), a process by 
which polarized epithelial cells develop increased migratory 
capacity, invasiveness, resistance to apoptosis and increased 
production of extracellular matrix, ultimately acquiring a 
mesenchymal cell phenotype [81]. Loss of expression of 
E-cadherin, the main constituent of the adherens junctions, 
is a hallmark of EMT. In somatotropinomas, E-cadherin 
expression correlates positively with GH and IGF-1 
secretion and and with somatostatin analogue treatment, 
and negatively with tumor size and invasiveness [82]. 
Interestingly, the characteristics of somatotropinomas with 
low E-cadherin expression recapitulate the phenotype 
described in the AIPmut positive setting (unpublished data 
from our group). A function of AIP as a regulator of the 
adherens junctions in the somatotroph cells, suggested by 
our results, would explain why somatotroph cells acquire an 
EMT phenotype in the setting of AIP deficiency.
Finally, we found that AIP is able to bind the 
enzyme SOD1, required for the conversion of superoxide 
to hydrogen peroxide, a mechanism that counteracts 
oxidative stress [83]. Rat somatotropinoma-derived GH3 
cells secrete SOD1, which, via activation of a muscarinic 
M1 receptor, reduces the activity of the MAPK1 signaling 
pathway, by inhibiting MAPK3 phosphorylation, reducing 
cell proliferation [84, 85]. On the other hand, accumulation 
of free radicals as a result of defective enzyme function 
can lead to neurotoxicity, as it happens in SOD1 mutation 
associated familial amyotrophic lateral sclerosis, or 
to malignant transformation in different tissues [83]. 
Molecular chaperones such as HSP70 and HSPA8 
regulate SOD1 function and prevent its aggregation [86]. 
We hypothesize that AIP could form part of this complex, 
therefore regulating the activity of SOD1. 
It was not completely unexpected to find that AIP 
overexpression has no effect on the expression of its 
interacting partners at the transcriptional level. Besides the 
fact that AIP does not have a known direct transcriptional 
effect, this co-chaperone is highly expressed in the 
somatotroph cells under basal conditions. Therefore, it is 
unlikely that AIP overexpression should have any acute 
transcriptional effects, even if indirect. However, the role 
of AIP overexpression under certain stimuli, for instance, 
in somatotropinomas treated with somatostatin analogues, 
might have a role on the posttranscriptional regulation of 
other proteins. Likewise, overexpression of multiple AIP 
interacting partners had no effect on the proliferation of 
GH3 cells. Overexpression of TUBB2A had a small, but 
significant effect on reducing cell proliferation at 48h 
compared with the same condition at 24 h. HSPA5, HSPA8, 
HSPA9, HSP90AA1, HSPA90AB1, NME1, SOD1, TUBB 
and TUBB2A are highly expressed in the cells and have no 
known direct oncogenic effects. 
We acknowledge the shortcomings of our study. 
Ideally, the pull-down experiments should had been 
done in lysates from human pituitary cells, but the lack 
of commercially available human pituitary cell lines and 
the difficulty to obtain fresh normal pituitary tissue from 
autopsy specimens in a quantity enough as to optimize 
and perform the experiments precluded the use of such 
material. Although a rat pituitary cell line was used for the 
pull-down experiments, we overcame this disadvantage 
by validating our results using human proteins. Finally, 
concerning the validation experiments, it would be 
desirable, but extremely impractical, to validate all 
the protein interactions identified. Interactions of AIP 
with novel partners have been fully validated, but it is 
possible that some of the other proteins identified (and 
not validated) could represent true interactions, providing 
opportunity for further experiments. While the finding of 
new chaperones interacting with AIP has shed light on 
the repertoire of interacting partners of AIP, it has also 
increased the number of chaperone-client proteins that 
could be regulated by the co-chaperone activity of AIP. 
Although mapping all these possible indirect interactions 
would be complicated, future studies could concentrate on 
determining which interactions of these chaperones in the 
somatotroph cells are mediated by AIP. 
Oncotarget14www.impactjournals.com/oncotarget
CONCLUSIONS
Several novel protein partners were identified and 
validated for AIP in somatotroph cells. Interactions with 
HSP70 family members HSPA5 and HSPA9 expand 
the repertoire of heat-shock proteins that could be 
modulated by AIP, opening a new window for possible 
anti-tumorigenic functions of AIP as a regulator of stress-
induced heat-shock protein functions. AIP also binds 
SOD1, an anti-oxidative protein with anti-proliferative 
potential. In addition, novel molecular interactions with 
the cytoskeletal proteins TUBB and TUBB2A and the 
cytoskeletal regulator NME1 indicate a possible role for 
AIP as a regulator of cytoskeletal organization and on the 
integrity of the adherens junction, which might be a novel 
mechanism for the complex tumor suppressor function of 
AIP in the pituitary gland. The study of this mechanism 
could be the focus of future studies.
METHODS
Protein synthesis and pull-down assays
The human AIP variants listed in Table 1 were 
obtained by site-directed mutagenesis (QuikChange II XL 
kit, Agilent Technologies, Santa Clara, CA, USA, 200521) 
from the p-THREE-E-AIP_WT plasmid [7]. Under 
IPTG induction, WT and mutant GST-AIP proteins were 
produced in BL21-PLyss E. coli and subjected to affinity 
(Glutathione Sepharose 4 Fast Flow, GE Healthcare, 
Little Chalfont, UK, 17-5132-02) and gel filtration 
chromatography. GST was obtained likewise and used 
as a negative control. Ten micrograms of each synthetic 
protein were used as baits for individual GST pull-down 
experiments against 2 mg of total protein from GH3 cells 
(ECACC, Porton Down, UK, 87012603), and eluates from 
four independent experiments for each bait protein were 
pooled together for MS analysis, as reported before [7]. 
Quantitative MS and identification of candidate 
AIP partners
Tandem mass tagging (TMTsixplex Label Reagent 
Set, Thermo Fisher Scientific, Waltham, MA, USA, 
90061) [87], and ion trap tandem MS (Orbitrap Velos 
Pro, Thermo Fisher Scientific) of the pull-down eluates 
were carried out at the King’s College London Denmark 
Hill Proteomics Facility, according to their standard 
procedures. Data were processed using the Proteome 
Discoverer version 1.3.0.339 (Thermo Fisher Scientific) 
software, and the sequences identified were searched in 
the UniProt database [12] via the Mascot v.2.2 platform 
[88]. Results were qualitatively analyzed and the MS 
fragmentation spectra were manually validated using the 
Scaffold 3.6 (Proteome Software) software. Only peptides 
with Mascot score ≥20 (to filter out non-significant results) 
and valid MS spectrum were considered for further 
analysis. The intensity value of each peptide in the GST 
experiment was subtracted from the value obtained for 
the same peptide in the rest of the experiments, and the 
normalized value for each of the mutants was divided by 
the normalized value for the WT experiment. Differential 
binding results are presented as fold-change, considering 
the results for the WT experiment in each case as 1. 
Candidate partners were selected based on the Mascot 
score, the number of unique peptides identified per 
protein (≥3 peptides was interpreted as highly probable 
candidates) and the differential intensity values among 
experiments. The human homologues of the candidate 
peptides selected were identified using the Blast tool in 
the UniProt database; the best match was selected in each 
case. The Ingenuity Pathways Analysis platform [89] 
was used for grouping the identified proteins in signaling 
pathways. Results for proteins involved in the ubiquitin-
proteasome pathway have been reported elsewhere [7].
Validation of protein-protein interactions
Plasmids containing the coding sequence for 
HSC70, HSP90AA1 and HSP90AB1 were a kind gift 
from Prof. Paul Chapple (Barts and The London School 
of Medicine). The coding sequence for SOD1 was cloned 
from human cDNA from HEK293 (human embryo kidney, 
ECACC 85120602) cells. For the rest of the candidate 
partners, plasmids were obtained from a repository 
(PlasmID DNA Resource Core, Harvard Medical School). 
All the sequences were sub-cloned into the pSF-CMV-
NH2-HA-EKT-NcoI plasmid (Oxford Genetics, Oxford, 
UK, OG93) to express N-terminally HA-tagged proteins. 
The plasmids pcDNA3.0-Myc-WT_AIP and pcDNA3.0-
Myc-AIP-R304* were used to express N-terminally 
Myc-tagged WT and p.R304* AIP, respectively [90], and 
the plasmid pSF-CMV-NH2-HA-EKT-Nco1-PRKACA 
was subjected to site-directed mutagenesis to obtain an 
N-terminal Flag tag. The final constructs are detailed in 
Supplementary Table 3.
Each of the plasmids was co-transfected with 
pcDNA3.0-Myc-WT_AIP plasmid in 10 × 106 HEK293 
cells for a total of 20 µg of plasmid DNA, with 1 µl 
of Lipofectamine 2000 (Invitrogen, Carlsbad, CA, 
USA, 11668027) per µg of DNA, according to the 
manufacturer’s instructions. Cells were harvested one 
day later by trypsinization and resuspended in 1.5 ml of 
lysis buffer, composed of 150 mM NaCl, 10 mM Tris-
Cl pH 7.5, 10% v/v glycerol, 1% v/v IGEPAL CA-630 
(Sigma-Aldrich, St. Louis, MO, USA, I8896) and 1 tablet 
per 50 ml Complete Protease Inhibitor Cocktail (Roche, 
Basel, Switzerland, 11836145001). After cleared by 
centrifugation, lysates were cleaned up by incubation with 
50 µl of Protein G Sepharose 4 Fast Flow (GE Healthcare 
17-0618-01), and divided in thirds for incubation with 
5 µg of anti-Myc (Sigma-Aldrich M4439), or anti-HA 
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mouse (Sigma-Aldrich H3663) monoclonal antibodies or 
mouse anti-IgG (Sigma-Aldrich I5381), as appropriate. 
Co-IP was performed as previously described [7], and 
the eluates were resolved by denaturing polyacrylamide 
gel electrophoresis and mouse anti-Myc and rabbit anti-
HA (Sigma-Aldrich H6908) Western blot. A mouse 
monoclonal anti-ACTB antibody (Sigma-Aldrich A1978) 
was used for ACTB immunoprecipitation. Detection was 
performed in an Odyssey Infrared Imaging System (LI-
COR, Lincoln, NE, USA) after incubation with secondary 
infrared fluorescent antibodies (LI-COR 926-68180 and 
926-32211). All the co-IP experiments were performed at 
least twice for confirmation.
Co-localization
For co-localization experiments, 5 × 104 HEK293 
cells per well were plated on an 8-well chamber slide 
(Thermo Fisher Scientific 154534) and grown for 48 h. 
Cells were pre-fixed for 2 min with 4% formaldehyde in 
PBS added to the medium, fixed for 10 more minutes after 
medium removal, washed thrice with PBS, permeabilized 
for 20 min at room temperature (0.1% triton X-100 
in PBS), blocked for 1 h (10% normal goat serum 
[VECTOR Laboratories, Burlingame, CA, USA, S-1000] 
in permeabilization buffer) and incubated overnight with 
primary antibodies against AIP (mouse monoclonal 1:500 
v/v [Novus, Littleton CO, USA, NB100-127], or rabbit 
polyclonal 1:100 v/v  [NBP1-31347], as appropriate) and 
one of the following: rabbit polyclonal anti-PRKACA 
(Proteintech, Rosemont, IL, USA, 5388-1-AP, 1:50 
v/v), rabbit monoclonal anti-GRP75 (Cell Signalling 
Technology, Danvers, MA, USA, 3593, 1:50 v/v), rabbit 
monoclonal anti-NEFL (Cell Signalling Technology 2837, 
1:100 v/v) or mouse monoclonal anti-TUBB2A (Abnova, 
Taipei, Taiwan,  H00007280-M03, 1:100 v/v). For actin 
staining, ActinGreen488 anti-ACTB probe (Invitrogen 
R37110) was used, following the manufacturer’s 
protocol, after incubation with the primary anti-AIP 
antibody. The cells were washed, incubated with 1:500 
v/v fluorescent secondary antibodies (Alexa Fluor 488 
Goat Anti-Mouse IgG [H+L] green and Alexa Fluor 568 
Goat Anti-Rabbit IgG [H+L] orange, Invitrogen A-11029 
and A-11036, respectively), washed again, and mounted 
with 4’,6-diamidino-2-phenylindole-containing mounting 
medium (UltraCruz Hard-set Mounting Medium, Santa 
Cruz Biotechnology, Dallas, TX, USA, sc-359850) for 
confocal microscopy analysis in an LSM 510 (Mark 4) 
Laser Scanning Confocal Microscope (Zeiss, Oberkochen, 
Germany). Z-stack images were obtained and visualized 
using the ImageJ version 2.0.0-rc-54/1.51g software [91]. 
Co-localization was analyzed on representative images 
with the Coloc 2 plugin, using the Costes threshold 
regression method and using the Pearson’s correlation 
coefficient to quantify co-localization [92–94]. 
Microarray expression analysis
Total RNA was extracted from five normal 
pituitaries (obtained from autopsies) as well as from 
twenty freshly frozen pituitary adenoma samples, including 
six somatotropinomas from patients carrying germline 
AIP variants (c.910C>T, p.R304* in three cases, and 
c.911G>A, p.R340Q, c.100–1025_279_357del, p.A34_
K93del and c.100–18C>T in one patient each), seven 
AIPmut negative somatotropinomas and seven clinically 
NFPAs, using the RNeasy plus mini kit (Qiagen, Hilden, 
Germany 74134). Patients were recruited as part of our 
cohort of pituitary adenoma patients and provided signed 
informed consent [6]. Global gene expression analysis 
was performed using Human Gene Chip HG-U133 Plus 
2.0 arrays (Affymetrix, Santa Clara, CA, USA). A double 
cut-off of false discovery rate <0.05 and fold change of ≥2 
was used to identify differentially expressed genes. The 
Ingenuity Pathway Analysis platform was used to analyze 
differentially expressed genes, and results were validated 
by RT-qPCR. Results were analyzed separately for each 
subgroup of samples and gene expression profiles were 
compared to seek differences between AIPmut positive 
and negative somatotropinomas, between each tumor type 
and the normal pituitary or between functioning tumors 
(somatotropinomas) and NFPAs. Data are presented 
only for genes with significant differential expression 
corresponding to protein families that were present also in 
the pull-down assays. 
Expression of AIP interacting partners under 
AIP overexpression 
For AIP overexpression experiments, 2.5 × 105 HEK 
293 or GH3 cells per well were plated in 12-well plates 
and transfected 24h later with 1µg of either pcDNA3.1(-) 
(empty vector), pcDNA3.0-Myc-WT_AIP, or an equivalent 
volume of water, and 2 µl of TurboFect (Thermo Fisher 
Scientific R0531) per well, according to the manufacturer’s 
instructions, in triplicate; each experiment was repeated at 
least twice for confirmation. RNA was extracted 24 hours 
later, as described before, and 500 ng of total RNA were 
reverse-transcribed using the SuperScriptIII First-Strand 
Synthesis Super Mix (Thermo Fisher Scientific 11752250), 
following the manufacturer’s protocol. Quantitative PCR 
was performed in a final volume of 10 µl, with 5 ng of 
cDNA per reaction, in triplicate, using the TaqMan Fast 
Advanced Master Mix (Thermo Fisher Scientific 4444557). 
The FAM-MGB labelled TaqMan expression assays 
Rn00565250_m1 (Hspa5), Rn00821191_g1 (Hspa8), 
Rn01402372_g1 (Hspa9), Rn00822023_g1 (Hsp90aa1), 
Rn01511686_g1 (Hsp90ab1), Rn00821755_g1 (Nme1), 
Rn00566938_m1 (Sod1), Rn00597407_m1 (Tubb5), and 
Rn01774446_m1 (Tubb2a), were used for experiments in 
GH cells, and Hs99999174_m1 (HSPA5), Hs03044880_gH 
Oncotarget16www.impactjournals.com/oncotarget
(HSPA8), Hs00945584_m1 (HSPA9), Hs00743767_sH 
HSP90AA1), Hs00607336_gH (HSP90AB1), Hs00533490_
m1 (SOD1), Hs02621161_s1 (NME1), Hs00742828_s1 
(TUBB), Hs00742533_s1 (TUBB2A), were used for 
HEK293 cells; Hs066610222_m1 (AIP) was used for both 
sets of experiments. The VIC-TAMRA labelled endogenous 
controls Rn00667869_m1 (Actb) and 4325788 (ACTB) were 
used for GH3 a and HEK293 cells, respectively. Reactions 
were carried out using the ViiA 7 Real-Time PCR System 
(Thermo Fisher Scientific) and results were analyzed via the 
2-DDCT method, normalized against empty vector control, and 
compared among experimental conditions. 
Cell proliferation assays under overexpression of 
AIP interacting partners
For cell proliferation experiments, 2.5 × 104 
GH3 cells per well were plated in 96-well plates and 
transfected 24 h later with 200 ng of HA-tagged plasmids 
to overexpress AIP interacting partners (Supplementary 
Table 3), empty vector or water, and 4 µl of Turbo Fect per 
well, in triplicate. Cell proliferation assays were performed 
at 24 and 48 h after transfection, using the CyQUANT 
Direct Cell Proliferation Assay (Thermo Fisher Scientific 
C35011), according to the manufacturer’s instructions. 
Fluorescence was detected using a FLUOstar Omega plate 
reader (BMG Labtech, Offenburg, Germany), normalized 
against blanks (cell culture medium only) and then against 
empty vector control, and compared among experimental 
conditions. Experiments were performed at least twice, for 
confirmation. 
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